4-Bromomethcathinone, also known as 4-BMC or Brephedrone, is a psychoactive substance and research chemical that falls within the phenethylamine, amphetamine, and cathinone chemical classes. As supported by scientific studies, its primary mode of action involves acting as a serotonin and norepinephrine reuptake inhibitor. However, it exhibits characteristics more in line with an antidepressant rather than a stimulant. It’s worth noting that certain 4-halogenated cathinones, including 4-bromomethcathinone, appear to share similarities with their amphetamine counterparts in terms of selective serotonergic neurotoxicity.
|CompTox Dashboard (EPA)||DTXSID401014169|
|Chemical and physical data|
|Molar mass||242.116 g·mol−1|
- In October 2015, 4-BMC became classified as a controlled substance in China.
- In Virginia, 4-Bromomethcathinone is categorized as a Schedule 1 substance.
1. What is 4-Bromomethcathinone (4-BMC)?
- 4-Bromomethcathinone, often abbreviated as 4-BMC, is a psychoactive drug and research chemical. It falls within the phenethylamine, amphetamine, and cathinone chemical classes.
2. How does 4-BMC affect the brain and body?
- 4-BMC primarily acts as a serotonin and norepinephrine reuptake inhibitor. However, it is noteworthy that its effects are more reminiscent of an antidepressant rather than a stimulant.
3. Is 4-BMC a controlled substance?
- The legal status of 4-BMC varies by country and region. As of the most recent information available:
- 4-BMC was classified as a controlled substance in China as of October 2015.
- In Virginia, USA, 4-bromomethcathinone is categorized as a Schedule 1 substance.
- It’s crucial to check local laws and regulations for the most up-to-date information regarding the legal status of 4-BMC in your area.
4. What are the potential risks associated with 4-BMC use?
- As with many psychoactive substances, the potential risks associated with 4-BMC use are not well-documented due to limited scientific research. However, it’s essential to exercise caution, as implications of this nature can have unpredictable effects and health risks.
5. Is 4-BMC used for any medical purposes?
- As of my last knowledge update in September 2021, 4-BMC had no recognized medical applications and was primarily encountered as a recreational or research chemical.
6. Where can I find more information about 4-BMC?
- Information about 4-BMC can be limited due to its status as a research chemical. You can refer to scientific literature, government health agencies, and research studies to learn more. However, exercise caution when seeking information about substances with limited safety profiles.
Please note that the legal and scientific landscape surrounding 4-BMC may have evolved since my last update in September 2021. Stay informed about this compound’s latest developments and regulations if you have any concerns or interests in its use or research.
- In 1999, Foley KF and Cozzi NV conducted research indicating that bromine substitution at the ring’s 3- or 4-position of methcathinone enhances its potency at serotonin uptake transporters. This research was presented at the Society for Neuroscience Abstracts (Volume 25, Issues 1–2).
- In June 2002, Foley KF and Cozzi NV explored the inhibition of transport function and desipramine binding at the human noradrenaline transporter. They also investigated protection by substrate analogs. Their findings were published in Naunyn-Schmiedeberg’s Archives of Pharmacology (Volume 365, Issue 6).
- In 2003, Foley KF and Cozzi NV investigated novel aminopropiophenones as potential antidepressants. This research was published in Drug Development Research (Volume 60, Issue 4) and is available in a PDF format.
- In August 2020, Wojcieszak J, Kuczyńska K, and Zawilska JB conducted a study on the effects of four synthetic cathinones, including 3-Chloromethcathinone and others, on the spontaneous locomotor activity and motor performance in mice. This research was published in Neurotoxicity Research (Volume 38, Issue 2).
- The “关于印发《非药用类麻醉药品和精神药品列管办法》的通知” is a document in Chinese issued by the China Food and Drug Administration on September 27, 2015. It pertains to the management of non-medical narcotics and psychotropic substances.
- On December 2, 2015, the Commonwealth of Virginia published the “18VAC110-20-322. Placement of Chemicals in Schedule I,” which addresses the classification of certain chemicals into Schedule I.